Sign in
Taking people in United StatesNo phase

Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)

Key facts

Who runs it
PSC Partners Seeking a Cure
Where
Boston, Dallas, Indianapolis, Miami, New Haven, Richmond, Rochester, Sacramento, and San Francisco, United StatesSee the 11 sitesAlso in 5 other countries, 7 sites
Trial code
Status
Recruiting
People taking part
2,000 people, planned
Started
6 May 2024
Expected to end
Jan 2031
Type of study
Observational
Record updated
13 October 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Adult patients between 18 and 75 years of age (inclusive) who can comprehend instructions, follow the study procedures and are willing to sign an Informed Consent Form (ICF)
  • Confirmed clinical diagnosis of large duct PSC

Who cannot take part

  • Clinically diagnosed infections (including acute cholangitis) and receiving treatment within the past 7 days; patients on chronic suppressive antibiotics for acute cholangitis will be allowed to enroll
  • Prior liver transplantation
  • Participants who are currently participating in an investigational PSC therapy clinical study or who have participated in such a study within the past 12 weeks
  • Clinically significant acute or chronic liver disease of an etiology other than PSC (including but not limited to metabolic-dysfunction associated steatohepatitis (MASH), PBC, HCV, HBV, or alcoholic hepatitis, Wilson's disease, alpha-1 antitryp-sin deficiency, acute or chronic drug-induced liver injury); Patients with PSC and elements of AIH overlap are allowed to enroll; Patients with metabolic dysfunction associated steatotic liver disease (MASLD) or benign steatosis are allowed to enroll
  • Evidence of current or historical decompensated cirrhosis based on the following clinical events:; Ascites > Grade 2 and requiring treatment; Esophageal or gastric variceal bleeding requiring hospitalization; Hepatic encephalopathy (as defined by a West Haven score ≥ 2); Spontaneous bacterial peritonitis defined as ascites absolute neutrophil count >250/mm3 in the absence of an intra-abdominal source of infection; AKI-HRS according to AASLD Guidelines (Flamm 2021); Portal hypertension based on a platelet count < 150 × 109/L and LSM > 15 kPa with clinical, laboratory, imaging and/or other relevant parameters
  • MELD 3.0 Score >15. For subjects on anticoagulation medication, baseline INR determination for MELD score calculation should take this use into account
  • History, evidence, or high suspicion of hepatobiliary malignancies or active colon cancer based on imaging, screening laboratory values, and/or clinical symptoms. Patients with a history of colon cancer who have undergone a colectomy and have no current evidence of colon cancer will be allowed to enroll in the study
  • Participants with current clinical or laboratory evidence of any severe, progressive, or uncontrolled disease, related or unrelated to PSC and which, in the opinion of the investigator, has an expected survival of less than 52 weeks
  • Small-Duct PSC
  • Clinically diagnosed secondary or IgG4-related sclerosing cholangitis
  • Hospitalization in the past 7 days
  • UDCA dose >28 mg/kg
  • Participants who are impaired, incapacitated, or incapable of completing study-related assessments or giving informed consent
  • Prisoners or participants who are involuntarily incarcerated
  • Absence of data in medical records to assess inclusion and exclusion criteria

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

Also in 5 other countries, 7 sites

  • Beth Israel Deaconess Medical CenterBoston, United StatesContact: Julie SheaTaking people
  • Massachusetts General HospitalBoston, United StatesContact: Gary ZhangTaking people
  • UT Southwestern Medical CenterDallas, United StatesContact: Stephen Rossi, PharmDNo longer taking part
  • Indiana UniversityIndianapolis, United StatesContact: Rebecca GerstorffTaking people
  • Schiff Center for Liver Diseases/University of MiamiMiami, United StatesContact: Cynthia Levy, MDTaking people
  • Yale UniversityNew Haven, United StatesContact: Marina SilveiraTaking people
  • Virginia Commonwealth UniversityRichmond, United StatesContact: Caitlin Hurst, BSTaking people
  • Mayo ClinicRochester, United StatesContact: Paige PowrieTaking people
  • UC DavisSacramento, United StatesContact: Samrrah RaoufTaking people
  • California Pacific Medical CenterSan Francisco, United StatesContact: Stefanie Roberts, BSTaking people
  • University of California San FranciscoSan Francisco, United StatesContact: Fawzy BarryTaking people

About the trial

What the trial wants to find out

Develop an appropriate real-world data comparator cohort to support the design, execution, and serve as an external control for interventional clinical trials in PSC.

The group in the trial

  • Adult patients with a confirmed diagnosis of large duct PSC.

    1. Adult patients between 18 and 75 years of age (inclusive) who can comprehend instructions, follow the study procedures and are willing to sign an Informed Consent Form (ICF). 2. Confirmed clinical diagnosis of large duct PSC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Global Multi-Center Prospective Observational Cohort to Support Drug Development in Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC)
Fit questions
Built from NCT06297993, who can take part
Record updated
13 October 2026